Regeneron’s pivotal trial for an ultra-rare disease fails the primary — but don't count them out at the FDA
Regeneron’s potentially pivotal study for a new drug to treat an ultra-rare and lethal bone disorder failed the primary endpoint — but the R&D team thinks they can still get the ball into the regulatory end zone with the positive data they have on hand.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
